NTHU’s Boron Neutron Capture Therapy Center Begins Treating Overseas Brain Cancer Patients
25.3.2020 12:00:00 EET | Business Wire | Press release
On February 14th the melodious strains of the fourth movement of Mahler's Fifth Symphony were heard inside the building of Tsing Hua Open pool Reactor (THOR) at National Tsing Hua University (NTHU) - for this is the favorite piece of music of a European woman who was here to undergo Boron Neutron Capture Therapy (BNCT) for a malignant brain tumor. This was her second course of treatment. The size of malignant glioma deep in her brainstem was reduced from 3.51 cm to 1.06 cm after the first treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200325005023/en/
The BNCT treatment mechanism. Since being converted for use in BNCT, the research reactor at NTHU has been used to treat over 130 patients. (Graphic: National Tsing Hua University)
In cooperation with the Taipei Veterans General Hospital (TVGH), NTHU has converted THOR for use in BNCT. To date, the treatment has provided a new lease on life to over 130 cancer patients from around the world.
According to Professor Chou Fong-in, BNCT is a target radiation therapy in which the patient is first injected with a boron-containing drug; once the drug has accumulated in the tumor, the neutron beam is used to irradiate the tumor for delivering curative doses specifically to tumors, while sparing normal tissue.
As explained by TVGH oncologist Chen Yi-wei, boron-10 drug contains the structure like essential amino acids, and cancer cells need lots of nutrients to support their abnormal proliferation. Thus cancerous cells absorb almost all the boron-10 before the normal cells have a chance to. The boron acts as a kind of explosive charge, and once the cancerous cells have got their fill of it, the neutron beam is used to “detonate” the charge, killing off the cancer cells.
The husband of the patient is a physician. He said that his wife used to be an avid tennis player, but four years ago she unexpectedly saw two balls flying towards her at the same time, a classic symptom of diplopia. A computerized tomography (CT) scan, however, later revealed a lesion of glioma in her brain, located deep inside her brainstem. After undergoing two craniotomies with gamma knife radiotherapy, the glioma relapsed and had turned malignant. On the advice of an expert of Radiation Oncology, they inquired about the treatment being offered at the TVGH.
According to Dr. Chen, the key requirements for BNCT are a boron-containing drug suitable for absorption by cancer cells, and a stable neutron source with appropriate energy spectrum. NTHU’s research reactor has been retrofitted to provide the neutron source. It is even better than the accelerator driven neutron source developed in Japan for use in hospitals.
NTHU and the Taoyuan City Government are planning to jointly develop a medical complex as part of the Taoyuan Aerotropolis to be built near the Taoyuan Airport. The BNCT will play a major role at the new facility, and will be used to treat both Taiwanese and overseas patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005023/en/
Contact information
Holly Hsueh
TEL: (886)3-5162006
e-mail: hoyu@mx.nthu.edu.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
K2 Partnering Solutions Appoints Srinivas Rao as Chief Executive Officer16.2.2026 11:00:00 EET | Press release
K2 Partnering Solutions, a global leader in consultative technology and talent solutions, today announced the appointment of Srinivas Rao as Chief Executive Officer. Srinivas is a seasoned global executive with more than 28 years of experience driving value creation, scalable growth, and operational transformation across digital, consulting, IT services, and business services. He brings deep expertise in leading complex, multi-market organisations and has successfully scaled $800M+ P&Ls, working closely with boards, sponsors, and executive leadership teams across the USA, UK, Europe, the Middle East, and APAC. Most recently, Srinivas served as Chief Business Officer and a member of the Executive Council at LTIMindtree, where he was accountable for growth acceleration, market expansion, strategic customer relationships, and operating performance across a highly complex regional footprint. During his tenure, he played a pivotal role in strengthening go-to-market execution, driving margin
Klarna Launches on Google Pay in the UK16.2.2026 10:00:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, is now available on Google Pay in the UK. Google Pay users in the U.K. can choose Klarna’s interest-free payment options at checkout. Raji Behal, Head of Western and Southern Europe, UK & Ireland at Klarna, said, “We’re really excited to bring Klarna’s fair, flexible and interest-free payment options to Google Pay users. This is a big moment for us and a major step towards our goal of being available at every checkout, everywhere. Together with Google, we’re making it easier than ever for millions of shoppers to choose Klarna and pay in a smarter, more transparent way — all from their phone.” Lisa Yokoyama, Director of Product Management at Google Paysaid: "Expanding our collaboration with Klarna to the U.K. underscores our goal to empower more people with the flexibility to pay how they choose. With people shopping on Google over a billion times a day, this broader footprint provides even more checkout options to help bus
Italy Sees Economic Boost From the Opening Weekend of the Olympic Winter Games Milano Cortina 202616.2.2026 10:00:00 EET | Press release
Visa, the Official Payment Technology Partner of the Olympic and Paralympic Winter Games, today released new data revealing consumer spending patterns in the Winter Games host locations1 during the opening weekend of the Olympic Winter Games Milano Cortina 2026. VisaNet data analysed by Visa Consulting & Analytics (VCA) shows the positive impact that Milano Cortina 2026 is having on commerce: Overseas Visa cardholders visits rose by more than 60%, with the largest share of visitors coming from the U.S. (+160% year-on-year), followed by China, Brazil, Canada and Japan. In Europe, Visa cardholders from Germany represent the largest share of visitors (31% year-on-year increase), followed by Switzerland, France and the UK. International Visa cardholders spent more than in the previous year, with the U.S. leading the year-on-year growth with a 125% increase in their spending, followed by Canada and Switzerland. Visitors from Germany, China and the U.S. ranked as the top spenders, with an av
New ECCO data show subcutaneous (SC) infliximab (Remsima ™ SC) effectively recaptures and maintains disease control after drug holiday16.2.2026 09:00:00 EET | Press release
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102.1 The data will be presented as a poster presentation at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held from February 18-21 in Stockholm, Sweden. “As immunogenicity is the most significant concern when restarting treatment with infliximab after an interruption, these results suggest that treatment persistence was maintained even in patients with immunogenicity,” said Dr. Marla Dubinsky, Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine at Mount Sinai. “It's reassuring to see that not only can we effectively recapture disease control with a convenient subcutaneous option, but that t
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom